EVO - Evotec gains on deal to understand autoimmune diseases

• German life sciences company Evotec SE ( NASDAQ: EVO ) ( OTCPK:EVOTF ) gained ~6% on Tuesday after announcing a partnership with German university Hannover Medical School to develop a molecular database to understand autoimmune disorders Sjögren's syndrome and systemic lupus erythematosus.
• The etiology of SjS and SLE are not very well known, even though the conditions remain two of the most common rheumatic autoimmune diseases.
• Per the terms, Hannover Medical School will collect biospecimens from SjS and SLE patients for analysis using Evotec's ( EVO ) data analysis platform PanOmics.
• Based on the analysis, the duo aims to create a unique longitudinal PanOmics database to understand SjS and SLE. The financial terms of the deal were not disclosed.
• Read: In September, bioinformatics company Adapsyn Bioscience announced a partnership with Evotec ( EVO ) to develop potential therapeutic candidates using microorganisms.

For further details see: